Ora, Inc. announced its participation as a major exhibitor in the Association for Research in Vision and Ophthalmology 2024 conference, and as host and convener of the Dry Horizons Symposium in partnership with Ophthalmology Innovation Source.
Ora booth #1630 at ARVO to highlight Blind Canvas Project, which creates AI-assisted artistic renderings of the lived experiences of the visually impaired
BOSTON, May 1, 2024 /PRNewswire/ -- Ora, Inc., the world’s leading partner for ophthalmic pharmaceutical and device development, today announced its participation as a major exhibitor in the Association for Research in Vision and Ophthalmology (ARVO) 2024 conference (May 5-9), and as host and convener of the Dry Horizons Symposium (May 3) in partnership with Ophthalmology Innovation Source. Both events will take place in Seattle.
“Team Ora is thrilled to be heading to ARVO which sets the benchmark as the premier showcase for the latest advancements in ophthalmic translational research,” stated Stuart B. Abelson, President, CEO, and Chairman of Ora. “For over 45 years and 85 approvals, Ora has helped ophthalmic innovators navigate product development successfully. Ora’s dedicated people, refined processes, and advanced technologies have consistently delivered the high-quality, reproducible data essential for advancing products through development. Our presentations at ARVO will spotlight the contributions of our global team and underscore our commitment to advancing the industry and enhancing patient lives worldwide.”
Just two days before the start of ARVO, Ora will co-present the first-ever Dry Horizons Symposium with Ophthalmology Innovation Source. The inaugural event at the Four Seasons Seattle will unite clinical leaders and industry innovators to address the massively underserved dry eye market.
“Modern digital technology and hours of daily screentime are exacerbating the already-here dry eye pandemic,” said Ora Chief Medical Officer Dr. Gustavo de Moraes, M.D., Ph.D., MPH. “Patients have few treatment options, especially outside the U.S., and those that exist often only work for a small subset of patients. Ora is convening the Dry Horizons Symposium to drive an important discussion on the critical need for new investment in the number, variety and speed to market of dry eye therapies globally.”
At ARVO, Ora will occupy booth #1630, which will feature Ora’s people, processes and technologies that together increase the likelihood of success for ophthalmic research programs around the globe. Ora will also showcase the Blind Canvas Project, a collaboration between Ora and BlindCAN Film Festival focused on creating new ways to understand the human experience of blindness. Assisted by AI image-generation software, Ora worked closely with individuals in the blind and low-vision community to transform their perspectives into expressive works of art. The goal of the Blind Canvas Project is to use visual stories and pieces to foster a genuine understanding of the lives and experiences of individuals living with inherited retinal diseases, childhood visual impairments, and other conditions leading to blindness.
Ora will also be exhibiting a robust slate of original research presentations at ARVO as detailed in the schedule below.
ARVO 2024 ORA RESEARCH PRESENTATION SCHEDULE
Mon., May 6
| Poster | Presenter | Time (PDT) | Poster # |
| “Interim Evaluation of the | Paul Gomes | 8:30 - 10:15 AM | 1956 - B0356 |
Tues., May 7
| Poster | Presenter | Time (PDT) | Poster # |
| “A Comparison of Lissamine | Dr. Mark Abelson | 8:30 - 10:15 AM | 2939 - A0098 |
| “Measuring Palpebral | Dr. Ethan | 8:30 - 10:15 AM | 2953 - A0112 |
| “Comparison Study Methods | Sadie Burnham | 8:30 - 10:15 AM | 2928 - A0087 |
| “Does an Ocular Lubricant | Dr. Jason Chin | 8:30 - 10:15 AM | 2963 - A0122 |
| “Factors Affecting Screen | Adam Hamm | 8:30 - 10:15 AM | 2954 - A0113 |
| “PLL-g PEG Eye Drops in | David Kleinman | 8:30 - 10:15 AM | 2974 - A0133 |
| “The Ora Variable Contrast | Dr. Gus De | 8:30 - 10:15 AM | 3218 - B0506 |
| “TL-925, a First-in-Class, | George W. Ousler | 8:30 - 10:15 AM | 2965 - A0124 |
| “Evaluation of Visual | Keith Lane | 1:15 - 3:00 PM | 3334 - A0219 |
Thurs., May 9
| Poster | Presenter | Time (PDT) | Poster # |
| “Ora Tablet Based Contrast | Ethan Bensinger | 8:00 - 9:45 AM | 5691 - B0097 |
About Ora Inc.
Ora is the world’s leading full-service ophthalmic drug and device development firm with offices in the United States, United Kingdom, Australia, and Asia. For over 45 years, we have proudly helped our clients earn more than 85 product approvals. We support a wide array of organizations, from start-ups to global pharmaceutical and device companies, to efficiently bring their new products from concept to market. Ora’s preclinical and clinical models, unique methodologies, and global regulatory strategies have been refined and proven across thousands of global projects. We bring together the world’s most extensive and experienced team of ophthalmic experts, R&D professionals, and management executives to maximize the value of new product initiatives. For more information, please visit http://www.oraclinical.com and follow us on LinkedIn.
Ora® and Ora Logo are registered trademarks of Ora, Inc.
MEDIA CONTACT
Anne Marie Jedraszczak
ajedraszczak@oraclinical.com
View original content:https://www.prnewswire.com/news-releases/ora-inc-to-showcase-latest-technologies-and-research-at-arvo-2024-convene-groundbreaking-ophthalmic-symposium-dry-horizons-302132046.html
SOURCE Ora, Inc.
